Mereo BioPharma (MREO) Receivables - Other (2017 - 2023)

Mereo BioPharma (MREO) has 6 years of Receivables - Other data on file, last reported at $2.0 million in Q4 2023.

• Receivables - Other for Q4 2023 came in at $2.0 million, up 118.18% year-over-year; the trailing twelve-month figure through Dec 2023 was $2.0 million (up 118.18% YoY), and the FY2023 annual result was $2.0 million, changed N/A from the prior year.
• Receivables - Other improved to $2.0 million in Q4 2023 per MREO's latest filing, from $893771.4 in the prior quarter.
• Over five years, Receivables - Other peaked at $2.0 million in Q4 2023 and troughed at $735434.6 in Q4 2019.
• A 4-year average of $1.2 million and a median of $1.1 million in 2020 frame the typical range for Receivables - Other.
• The sharpest annual moves came in 2019 and 2023: Receivables - Other fell 6.15% in 2019, then soared 118.18% in 2023.
• A 4-year view of Receivables - Other shows it stood at $735434.6 in 2019, then surged by 82.42% to $1.3 million in 2020, then tumbled by 33.38% to $893771.4 in 2022, then soared by 118.18% to $2.0 million in 2023.
• Business Quant data shows MREO's Receivables - Other at $2.0 million in Q4 2023, $893771.4 in Q4 2022, and $1.3 million in Q4 2020.